CIPLA:NSE-Cipla Limited (INR)

COMMON STOCK | Drug Manufacturers-General | NSE

Last Closing Price

INR 888.65

Change

+10.20 (+1.16)%

Market Cap

INR 721.37B

Volume

0.01B

Average Target Price

INR 937.43 (+5.49%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other dosage forms consists of injectables and biosimilars. Cipla Limited has collaboration with CSIR-Indian Institute of Chemical Technology for the development of medication for the treatment of COVID-19; and partnership with Karwa Ltd. for the commercialization of antibody detection kits for COVID-19, as well as the Premier Medical Corporation Private Limited for the commercialization of the rapid antigen test kits for COVID-19. The company was founded in 1935 and is headquartered in Mumbai, India.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-05 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
GLAND:NSE Gland Pharma Limited

-39.15 (-1.48%)

INR430.55B 44.09 31.06
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+118.10 (+4.71%)

INR428.13B 34.47 18.28
ABBOTINDIA:NSE Abbott India Limited

+88.65 (+0.58%)

INR321.31B 49.50 32.05
GLAXO:NSE GlaxoSmithKline Pharmaceutical..

+14.95 (+1.03%)

INR246.45B 51.34 32.01
PFIZER:NSE Pfizer Limited

+210.35 (+4.02%)

INR242.79B 48.55 29.69
SANOFI:NSE Sanofi India Limited

+100.10 (+1.32%)

INR175.78B 32.67 19.74
MARKSANS:NSE Marksans Pharma Limited

+4.00 (+5.62%)

INR30.58B 15.04 8.99
SMSPHARMA:NSE SMS Pharmaceuticals Limited

-0.05 (-0.03%)

INR12.83B 27.98 14.31
TTKHLTCARE:NSE TTK Healthcare Limited

+16.70 (+2.90%)

INR8.41B 22.91 17.06
KOPRAN:NSE Kopran Limited

+9.40 (+5.24%)

INR8.03B 15.63 9.48

ETFs Containing CIPLA

Symbol Name Weight Mer Price(Change) Market Cap
NFTY First Trust India NIFTY 5.. 0.00 % 0.80 %

+1.03 (+2.47%)

INR6.31M

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.51% 64% D 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.51% 64% D 51% F
Trailing 12 Months  
Capital Gain 50.17% 73% C 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.17% 73% C 32% F
Trailing 5 Years  
Capital Gain 65.38% 36% F 66% D
Dividend Return 1.86% 30% F 21% F
Total Return 67.24% 36% F 65% D
Average Annual (5 Year Horizon)  
Capital Gain 11.70% 27% F 65% D
Dividend Return 0.38% 40% F 29% F
Total Return 12.08% 27% F 65% D
Risk Return Profile  
Volatility (Standard Deviation) 31.71% 55% F 73% C
Risk Adjusted Return 38.11% 55% F 76% C
Market Capitalization 721.37B 100% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 32.25 67% D+ 34% F
Price/Book Ratio 4.28 58% F 22% F
Price / Cash Flow Ratio 23.51 92% A- 21% F
EV/EBITDA 16.76 75% C 39% F
Management Effectiveness  
Return on Equity 10.85% 36% F 65% D
Return on Invested Capital 7.44% 25% F 59% F
Return on Assets 6.43% 36% F 80% B-
Debt to Equity Ratio 15.03% 57% F 48% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.48 55% F 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector